Results 11 to 20 of about 5,664,310 (354)

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.

New England Journal of Medicine, 2019
BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium-glucose cotransporter 2 (SGLT2), exploratory results have ...
V. Perkovic, M. Jardine, B. Neal, Severine Bompoint, H. Heerspink, D. Charytan, Robert Edwards, R. Agarwal, G. Bakris, S. Bull, C. Cannon, G. Capuano, P. Chu, D. de Zeeuw, T. Greene, A. Levin, C. Pollock, D. Wheeler, Yshai Yavin, Hong Zhang, B. Zinman, G. Meininger, B. Brenner, K. Mahaffey   +23 more
semanticscholar   +1 more source

Sugar and Type 2 diabetes [PDF]

, 2016
Background: Consumption of sugar, specifically sugar-sweetened beverages, has been widely held responsible by the media for the global rise in Type 2 diabetes (T2DM).
Lean, Michael E.J., Te Morenga, Lisa
core   +1 more source

Interventions for prevention of type 2 diabetes in relatives:A systematic review [PDF]

, 2017
The relatives and partners of people with type 2 diabetes are at increased risk of developing type 2 diabetes. This systematic review examines randomized controlled trials, written in English that tested an intervention, which aimed to modify behaviors ...
Dimova, Elena Dimcheva, Evans, Josie M.M., Mohan, Andrea Rene Mary, Swanson, Vivien   +3 more
core   +4 more sources

Chapter 29: Male sexual dysfunction in type 2 diabetes

South African Family Practice, 2018
No abstract available.
Society for Endocrinology Metabolism and Diabetes of South Africa Type 2 Diabetes Guidelines Expert Committee
doaj   +1 more source

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

New England Journal of Medicine, 2019
BACKGROUND The cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium–glucose cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is undefined. METHODS We randomly assigned patients with type 2 diabetes who
S. Wiviott, I. Raz, M. Bonaca, Ofri Mosenzon, Eri Toda Kato, A. Cahn, Michael G. Silverman, Thomas A. Zelniker, J. Kuder, S. Murphy, Deepak L. Bhatt, Lawrence A Leiter, Darren K Mcguire, J. Wilding, C. Ruff, I. Gause-Nilsson, M. Fredriksson, P. Johansson, A. Langkilde, M. Sabatine   +19 more
semanticscholar   +1 more source

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.

New England Journal of Medicine, 2021
BACKGROUND Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist that is under development for the treatment of type 2 diabetes.
J. Frias, M. Davies, J. Rosenstock, Federico Pérez Manghi, L. Fernández Landó, B. Bergman, Bing Liu, Xuewei Cui, K. Brown   +8 more
semanticscholar   +1 more source

Insulin resistance in type 1 diabetes: what is ‘double diabetes’ and what are the risks? [PDF]

, 2013
In this review, we explore the concept of ‘double diabetes’, a combination of type 1 diabetes with features of insulin resistance and type 2 diabetes.
A Caixas, AM Taylor, B Conway, B Teupe, B. M. Fisher, BF Voight, CT Prince, D Williams, D Yazici, DB Savage, DM Maahs, DM Maahs, DM Nathan, EA Nikkila, ER Christ, ES Kilpatrick, G Pambianco, G Perseghin, G Perseghin, G Roglic, G Ruotolo, H. M. Colhoun, HM Colhoun, IE Schauer, J Frystyk, J Guy, J Yip, J-L Selam, J. R. Petrie, JA Edge, JB Ferriss, JC Zgibor, JQ Purnell, JQ Purnell, JR Erbey, JR Petrie, JT Lahtela, KJ Nadeau, L Hodson, LM Thorn, M Kacerovsky, MR Taskinen, MR Taskinen, MR Taskinen, N Chaturvedi, N Sattar, N. Sattar, P Nevalainen, P Petruzzo, R Sinha, RA Heptulla, RW James, S Makimattila, S Norbert, S Vella, S. J. Cleland, SC Bain, SD Sibley, SJ Livingstone, SR Vethakkan, The Diabetes Control and Complications Trial Research Group, TJ Orchard, TJ Wilkin   +62 more
core   +3 more sources

Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.

New England Journal of Medicine, 2021
BACKGROUND Finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, has favorable effects on cardiorenal outcomes in patients with predominantly stage 3 or 4 chronic kidney disease (CKD) with severely elevated albuminuria and type 2 ...
B. Pitt, G. Filippatos, R. Agarwal, S. Anker, G. Bakris, P. Rossing, A. Joseph, P. Kolkhof, C. Nowack, Patrick Schloemer, L. Ruilope   +10 more
semanticscholar   +1 more source

The PPARγ2 P12A polymorphism is not associated with all-cause mortality in patients with type 2 diabetes mellitus [PDF]

, 2016
The high mortality risk of patients with type 2 diabetes mellitus may well be explained by the several comorbidities and/or complications. Also the intrinsic genetic component predisposing to diabetes might have a role in shaping the risk of diabetes ...
Alberico, Federica, Bacci, Simonetta, Cignarelli, Mauro, Copetti, Massimiliano, De Cosmo, Salvatore, Fontana, Andrea, Lamacchia, Olga, Marucci, Antonella, Mercuri, Luana, Pacilli, Antonio, Palena, Antonio, Prudente, Sabrina, Trischitta, Vincenzo, Viti, Raffaella   +13 more
core   +1 more source

Consumption of sugar sweetened beverages, artificially sweetened beverages, and fruit juice and incidence of type 2 diabetes: systematic review, meta-analysis, and estimation of population attributable fraction. [PDF]

, 2015
OBJECTIVES: To examine the prospective associations between consumption of sugar sweetened beverages, artificially sweetened beverages, and fruit juice with type 2 diabetes before and after adjustment for adiposity, and to estimate the population ...
Bhupathiraju, Shilpa N, Forouhi, Nita G, Hayashino, Yasuaki, Imamura, Fumiaki, Mursu, Jaakko, O’Connor, Laura, Ye, Zheng   +6 more
core   +8 more sources